Pure Global AI
NCT06399835Recruiting

Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Comparing Enavogliflozin and Pioglitazone as Add-ons to Metformin With/Without Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes
Seoul National University Bundang HospitalPhase 4ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Type 2 Diabetes
Drug/Device/Intervention
Enavogliflozin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Seoul National University Bundang Hospital
Location
Seongnam-si, South Korea
Timeline & enrollment
Phase
Phase 4
Start date
Feb 01, 2024
End date
Dec 01, 2026
Enrollment
120 participants
Primary outcome

Changes of HbA1c from the baseline

Summary

The current study aimed to thoroughly compare a thiazolidinedione and an sodium-glucose
 cotransporter-2 (SGLT2) inhibitor regarding various clinical issues including
 atherosclerosis. Enavogliflozin is compared to Pioglitazone in the glucose-lowering effects
 of adding to the treatment of patients with type 2 diabetes whose HbA1c levels are not
 controlled by Metformin with or without DPP-4 inhibitors. Additionally, the study will
 compare changes in other metabolic or cardiovascular risk factors, such as triglycerides,
 high density lipoprotein cholesterol (HDLc), uric acid, blood pressure, and inflammatory
 markers, between the two drugs.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06399835
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06399835 through Pure Global AI's free database. This Phase 4 trial is sponsored by Seoul National University Bundang Hospital and is currently Recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.